Trial Profile
Double-blind, Randomized, Dose Escalation Study of the Efficacy and Safety of ZK 245186 Ointment in Concentrations of 0.01%, 0.03%, and 0.1% Over 4 Weeks in Patients With Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jun 2023
Price :
$35
*
At a glance
- Drugs Mapracorat (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Bayer
- 23 Dec 2014 New trial record